A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure

Journal of the American College of Cardiology

Volumn 61, Issue 2, 2013, Pages 131-142

  Savarese, Gianluigi ^a   Costanzo, Pierluigi ^a,b   Cleland, John George Franklin ^b   Vassallo, Enrico ^a   Ruggiero, Donatella ^a   Rosano, Giuseppe ^c   Perrone Filardi, Pasquale ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF HULL   (United Kingdom)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

ACE I; angiotensin receptor blocker; angiotensin converting enzyme inhibitor; ARB; clinical events

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ARTICLE; CARDIOVASCULAR DEATH; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE DURATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84871922515     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.10.011     Document Type: Article

References (48)

1. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
2. R.J. Gibbons, J. Abrams, K. Chatterjee ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 41 2003 159 168
3. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
4. K.M. Fox EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
5. S. MacMahon, N. Sharpe, G. Gamble Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril J Am Coll Cardiol 36 2000 438 443
6. K.K. Teo, J.R. Burton, C.E. Buller Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 102 2000 1748 1754
7. B. Pitt, B. O'Neill, R. Feldman The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function Am J Cardiol 87 2001 1058 1063
8. E. Braunwald, M.J. Domanski, S.E. Fowler Angiotensin-converting-enzyme inhibition in stable coronary artery disease PEACE Trial Investigators N Engl J Med 351 2004 2058 2068
9. S.E. Nissen, E.M. Tuzcu, P. Libby Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial JAMA 292 2004 2217 2225
10. M. Marre, M. Lievre, G. Chatellier Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) BMJ 328 2004 495 500
11. DREAM Trial Investigators J. Bosch, S. Yusuf et al. Effect of ramipril on the incidence of diabetes N Engl J Med 355 2006 1551 1562
12. J.L. Rouleau, W.J. Warnica, R. Baillot Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery Circulation 117 2008 24 31
13. G.R. Dagenais, J. Pogue, K. Fox, M.L. Simoons, S. Yusuf Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials Lancet 368 2006 581 588
14. F. Cipollone, M.L. Fazia, A. Mezzetti Role of angiotensin II receptor blockers in atherosclerotic plaque stability Expert Opin Pharmacother 7 2006 277 285
15. A.D. Struthers Aldosterone escape during ACE inhibitor therapy in chronic heart failure Eur Heart J 16 1995 103 106
16. J.P. Casas, W. Chua, S. Loukogeorgakis Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis Lancet 366 2005 2026 2033
17. N. Chaturvedi, M. Porta, R. Klein Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials Lancet 372 2008 1394 1402
18. A.K. Sjølie, R. Klein, M. Porta Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial Lancet 372 2008 1385 1393
19. C. Demers, J.J. McMurray, K. Swedberg Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure JAMA 294 2005 1794 1798
20. H.H. Parving, H. Lehnert, J. Bröchner-Mortensen The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
21. B.M. Brenner, M.E. Cooper, D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
22. T. Berl, L.G. Hunsicker, J.B. Lewis Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy Collaborative Study Group Ann Intern Med 138 2003 542 549
23. J. Kondo, T. Sone, H. Tsuboi Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease Am Heart J 146 2003 E20 E25
24. H. Lithell, L. Hansson, I. Skoog The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial J Hypertens 21 2003 875 886
25. E. Imai, S. Ito, M. Haneda, J.C. Chan, H. Makino ORIENT Investigators Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design Hypertens Res 29 2006 703 709
26. S. Yusuf, H.C. Diener, R.L. Sacco Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 2008 1225 1237
27. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators S. Yusuf, K. Teo et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 2008 1174 1183
28. NAVIGATOR Study Group J.J. McMurray, R.R. Holman et al. Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1477 1490
29. H. Haller, S. Ito, J.L. Izzo Jr Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes N Engl J Med 364 2011 907 917
30. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J Clin Epidemiol 62 2009 1006 1012
31. G. Savarese, S. Paolillo, P. Costanzo Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials J Am Coll Cardiol 60 2012 1192 1201
32. A. Detsky, C. Naylor, K. O'Rourke, A. McGeer, K. L'Abbé Incorporating variations in the quality of individual randomized trials into meta-analysis J Clin Epidemiol 45 1992 255 265
33. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy The Collaborative Study Group N Engl J Med 329 1993 1456 1462
34. G. Maschio, D. Alberti, G. Janin Effect of the angiotensin-converting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group N Engl J Med 334 1996 939 945
35. L.C. van Vark, M. Bertrand, K.M. Akkerhuis Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients Eur Heart J 33 2012 2088 2097
36. S. Sharp, J. Sterne Meta-analysis 1 Stata Technical Bulletin Reprints 7 1998 100 108
37. P. Costanzo, P. Perrone-Filardi, M. Petretta Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients J Hypertens 27 2009 1136 1151
38. H.T. Davies, I.K. Crombie, M. Tavakoli When can odds ratios mislead? BMJ 316 1998 989 991
39. A. Whitehead Meta-Analysis of Controlled Clinical Trials 2002 John Wiley & Sons Inc Chichester, England 4
40. S.W. Raudenbush Analyzing effect sizes: random-effects models H.M. Cooper, L.V. Hedges, J.C. Valentine, The Handbook of Research Synthesis and Meta-Analysis 2009 Russell SAGE Foundation New York, NY 306 307
41. S.J. Sharp Meta-analysis regression Stata Technical Bulletin 42 1998 16 22
42. S.G. Thompson, S.J. Sharp Explaining heterogeneity in meta-analysis: a comparison of methods Stat Med 18 1999 2693 2708
43. J.L. Peters, A.J. Sutton, D.R. Jones, K.R. Abrams, L. Rushton Comparison of two methods to detect publication bias in meta-analysis JAMA 295 2006 676 680
44. W.L. Baker, C.I. Coleman, J. Kluger Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease Ann Intern Med 151 2009 861 871
45. S. Bangalore, S. Kumar, J. Wetterslev, F.H. Messerli Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials BMJ 342 2011 d2234 d2248
46. F.A. McAlister Renin Angiotension System Modulator Meta-Analysis Investigators Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials Eur Heart J 33 2012 505 518
47. S.G. Thompson, J.P.T. Higgins How should meta-regression analyses be undertaken and interpreted Statist Med 21 2002 1559 1573
48. ONTARGET Investigators S. Yusuf, K.K. Teo et al. Telmisartan, ramipril, or both in patients at high risk for vascular events ONTARGET Investigators N Engl J Med 358 2008 1547 1559